

Cont B3
acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO:2 when said expression system is present in a host cell.

By

11. (AMENDED) A process for producing an IGS1 polypeptide comprising culturing a host cell of claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.

12. (AMENDED) A process for producing a cell which produces an IGS1 polypeptide comprising transforming or transfecting a cell with the expression system of claim 6, wherein the cell produces an IGS1 polypeptide.

13. (AMENDED) An IGS1 polypeptide comprising an amino acid sequence, which is at least 80% identical to the amino acid sequence of SEQ ID NO:2.

B5

16. (AMENDED) A method for the treatment of a subject in need of enhanced activity or expression of the IGS1 polypeptide of claim 13 comprising at least one of:

(a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; and

(b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the IGS1 polypeptide of SEQ ID NO:2 or a nucleotide sequence complementary to said nucleotide sequence, wherein the polynucleotide directs production of said polypeptide activity in vivo.

17. (AMENDED) A method for the treatment of a subject having need to inhibit activity or expression of a IGS1 polypeptide as claimed in claim 13 comprising at least one of:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

*Att
B5*

- (a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide;
- (b) providing to the subject an isolated polynucleotide that inhibits the expression of the nucleotide sequence encoding said polypeptide; and
- (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand.

18. (AMENDED) A process for diagnosing a disease or a susceptibility to a disease in a subject, wherein the disease is related to expression or activity of the IGS1 polypeptide of claim 13 in a subject comprising at least one of:

- (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said IGS1 polypeptide in the genome of said subject; and
- (b) analyzing for the presence or amount of the IGS1 polypeptide expression in a sample derived from said subject.

B6
Please add the following new claim:

25. (NEW) The isolated polynucleotide of claim 1, wherein the nucleotide sequence has at least 90% identity to the nucleotide sequence of (a) and (b).

REMARKS

Applicants respectfully request that the amendments to the specification and the claims be entered before the application is examined.

The amendment to the specification corrects a citation. This amendment does not add new matter.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com